Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Anatomy of a Flagship Asset: Oncolytics Biotech

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 15, 2023 11:03pm

268 Views

Post# 35499454

RE:RE:RE:RE:Anatomy of a Flagship Asset: Oncolytics Biotech

I agree Fox.

Pehraps money is the bank is strength in negotiations. In fact, it has to be.

Also we do not know when that piece was commissioned or prepared.

Nor does the promo dept know everything about what is happening in deal making right now.

Or so we tell outselves.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record